Floatz logo

Polatuzumab

Diffuse Large B Cell Lymphoma (DLBCL)

Beijing Tongren HospitalPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

270 Active assets in the Diffuse Large B Cell Lymphoma (DLBCL) cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Polatuzumab is also rated in:

Aggressive Non-Hodgkin LymphomaDormant
B
Indicative ·
60 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →
mantle cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →